Not exactly for this thread [there's another already on the topic], but think the feeder setting is like 75,000 per 6 hours i.e. 300,000 day. Front page returns and daily validations [234,035 yesterday] are well behind that number i.e. hosts are sucking way more than they can chew. WCG caps at 35 per core In progress [all sciences combined], so eventually, anyone who maxes out the buffers will be filled to the brim, and can only fetch as much as these hosts return.

/ot

Thanks.
I am calm now. In summary:

I think that such questions for legitimacy and ethics can be skipped if the code, methods and results get public from beginning or latter on.
In ideal the SETI project is good primer.

To me it is not strange or surprise that bio computations are not going open source. Too risky. The science is real Jurassic park.

For example the nickname of the admin forum can be changed.

I like present admin though.

The bad thing is that Chinese (for example) people don't thrust and they make their community grid albeit again with closed source.

So in some sense WCG start lacking the letter W.

I believe in that here are collected good people and GHz clocks.

So I rely on others autorities as founder and team behind project and opted in OpenZika. I participate in all WCG projects, except CEP2 because my computer is slow. (And because of the summer only android projects two for the summer.)

I read the policy forum rules. But if someone find something crude, please, flagged.

I don't think codes and agreements are necessary as long as the researchers keep an up to date open data base that is publicly accessible.

Seems that would save a lot of angst and paper work to me...

you're not asking if WCG & SRI servers can handle that much feeding?!



Are you crazy? What you propose here "publicly" is PUNISHED BY LAW!

Do you really want to go to "jail vacation"?

"Re: Question the ethics and legitimacy of this project for BOINC
OK I hope the following can at least clarify a few things raised in these posts and give you a better idea of where I come from and why I am involved...."


No one is questioning the true altruistic desire to help and to try to find treatments or cures for œneglected diseases by the researchers of the Open Zika Project, Carolina Andrade, Alexander Perryman and Sean Ekins. My posting was not intended to be a personal attack. What they do is commendable. I simply question it™s appropriateness for BOINC.

Aside from the commercial connection to this project that started this entire discussion, which was confirmed by Ekins if you carefully read his response, only, perhaps, not for his company, is the argument that its a œneglected disease, ”as well as, the others this same team of researchers noted they wish to work on.

I also question the argument that there are no incentives for for-profit companies and that big pharma. isn™t working on these œneglected, yet related, diseases.

These are new companies and I believe may be using BOINC to play catch-up to companies that have been working on these diseases far longer. Perhaps, attempting to capitalize on the fear of Zika, which is, and has been for several months, so prevalent in the news, getting BOINC volunteers to create a shortcut for them- to give them a jump start. Right now they have nothing to form collaborative agreements or get grants based on, but once we supply them with a lot of data, they may, and probably will have possible candidates to begin studying by œother collaborators who will than license it.

I think if you really know what™s going on with this disease, youll see that vaccines, therapeutics and diagnostics are already on the way, with at least 2-3 vaccines/therapeutics going into human clinical trials this yr. This may make you too question its place on BOINC. You may feel, the more the merrier, but with so much going on already, other projects are probably more deserving of our time.

As far as Zika is concerned. Its not a œneglected disease. It may have been a few years ago, when thought to be isolated and was a low priority compared to Ebola and dengue--” when only a few companies were researching it. However, since the knowledge of it™s effects on newborns became known and it™s spread to 33 countries a/o Feb, 2016, and it™s spread since to more including the US, it™s gotten lots of attention. Zika will affect most, if not all of the world; it™s no longer an œorphan. However, none of that would have been known if others werent already working on it.

Much has been learned about Zika in just the past 6-9 mos. It™s known to be connected to the same mosquitos as other diseases and it™s part of the Flavivirus family. It can be spread by at least 2 different mosquitos. Its a threat to any female who is or ever wants to become pregnant-including small children. Anyone can get it and they ha™ve learned it can be spread by means other than a mosquito bite, so visiting an affected area isn't necessary to contract it. It also is now known to cause a serious neurological disorder in adults, as well as, its potential link to Guillain-Barre syndrome, a serious neurological disease that affects the immune system. It™s believed it can cause other physical deformities in infants and possibly sudden death. There is also some evidence now that it™s harbored in the testes of males who have contracted the disease long after the illnesses flu-like symptoms appear to have gone, as well as living on in females affecting future pregnancies.

Zika™s huge and is getting a lot of attention from govts.-research and grants, academia, big pharma. and small bio-techs alike around the world. The U.S. House of Representatives approved a bill (5.18.16) that aims to combat the Zika virus but it still needs to go to the Senate. While the bill would provide $622 million to fight the virus, the dollar amount is actually less than one-third of what President Obama was seeking.

Back in Feb, WHO's (World Health Organization) Dr. Kierny announced œabout 15 companies and groups were involved in the race to find a vaccine for the mosquito-borne virus, and there were at least two fairly advanced vaccine efforts: the U.S. National Institutes for Health*, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the privately-held Indian company Bharat Biotech International Limited.  Bharat and others had already been working on a Zika virus vaccine, spurred by the prevalence of dengue fever and chikungungya, which are both spread by the same mosquito carriers as Zika. The NIAID and the Scripps Research Institute were searching for potential drugs, while companies including Chembio Diagnostics Inc. were working on new diagnostic tests.

A/O Mar. 2, 2016, WHO said œ67 companies and research institutions were already working on a number of products (31 on diagnostics, 18 on vaccines, 8 on therapeutics, 10 on vector control plus others who had announced investigating their participation including giants like Pfizer and J&J), which are at various stages of early development. No vaccine or therapeutic had yet been tested on humans.  WHO also said regarding a vaccine: œ..pragmatic strategies will be needed to fast-track the development of a safe and effective product.

As noted above, there are numerous govt. and for-profit companies working on Zika and theyre not all small companies.

SANOFI, SA, a french pharmaceutical company, is not a small drug company and were one of the first to announce their research into Zika. They responded quickly to the WHOs declaration of a worldwide public health emergency and announced the establishment of a dedicated Zika vaccine development program the following day. The company had already successfully developed vaccines for other Flaviviruses, including yellow fever, Japanese encephalitis and dengue fever. “Dengue is, in fact, the closest known virus to Zika. Sanofi Pasteur said it will build on this expertise, its broad international scientific and public health collaborations, and its recent success in developing the first dengue vaccine to expedite the search for a candidate vaccine. (Sanofi Pasteur is the vaccine division of the Sanofi-Aventis Group who collaborated and developed with Acambis, Inc. the above noted vaccines, then bought Acambis out making it a wholly owned subsidiary. Dr Monath, now at NewLink Genetics, was Acambis Inc™s Chief Scientific Officer for 14 yrs. where he led the research & development of dengue, West Nile and yellow fever vaccines.)

Entrepreneur.com in Feb.said aside from France™s Sanofi Pasteur, Japan™s Takeda Pharmaceutical and the USs Glaxo-Smith Kline were also working on Zika vaccines. These are also listed in WHO documentation of the œCurrent Zika Pipeline dated 3.3.16.

MERCK has a collaboration with Newlink Genetics for its research on Ebola and Zika.

The two smaller biotechs leading the pack on a Zika vaccine, Inovio & NewLink Genetics, announced human clinical trials before the end of this yr.

One reason research has been able to be speeded up on this epidemic is because of its relation to Dengue and others of this same mosquitos borne diseases. The NIH and the companies who were previously doing research on those, can apply what they™ve learned to Zika and possibly tweak those vaccines already approved like Dengue or in trials like MERS for Zika.

Ekins is right. There may not be enough money involved in some neglected diseases for big pharma to do research on their own and they were left to small bio-techs and academia. However, now, for many, big pharmas are buying up small biotechs right & left to acquire their research, as well as, supporting the research of other promising bio-techs with collaborations and advance licensing deals. It seems neglected/orphan diseases and drugs are becoming big business and competition is getting fierce.

There are now numerous incentives for research in œneglected, otherwise known as Orphan diseases, treatments & vaccines. Among them:

1) The desperate need to find a cure & or treatment for diseases where none is currently available

2) Tax incentives for companies working on orphan treatments & vaccines

3) Collaboration with funding from larger biotech & pharmaceutical companies
It™s this collaboration that helps to keep the small bio-techs, with no drugs on the market to generate income, viable and able to continue to fund their research.

4) Collaborations with research done via academia.

5) Grants available for orphan disease research and development.
ie: Inovio has received about $135M in third party grants, including NIH & DARPA

6) œOrphan Drug granted status means expedited review from the FDA and other Drug regulatory agencies around the world for approval, as well as, speeded up development -possibly shortened & or fewer research trials. Normal vaccine research traditionally has taken 10 yrs+/-, while some of these potential Orphan Drugs/vaccines are in Ph 3 trials or approved, in half that time or less.

7) œOrphan Drug granted status means extended exclusivity of patented treatments, and vaccines, once approved.

The two Smaller Biotechs most in the lead working on ZIKA and its related diseases are:

INOVIO: has received about $135M in third party grants, including NIH & DARPA

ZIKA Using their SynCon process, rapidly generated a synthetic vaccine candidate that shows promise. They have already generated strong immune responses in animal models (large non-human = monkeys) with their vaccine and will initiate and conduct the first human trials in 2016 for Zika. *

EBOLA. Inovio is developing an Ebola preventive vaccine and treatment for those infected based on a $45 million DARPA grant received last year. In the first quarter, they reported that interim data from the phase I clinical study of INO-4212 Ebola vaccine in 75 healthy subjects showed it was safe, tolerable and generated strong T cell and antibody responses.

We plan to fully analyze the data from this clinical trial and report them in a publication. We are also excited by the demonstration of the protective efficacy of our vaccine against a lethal virus challenge in several nonhuman primate challenge studies, said the CEO.

MERS, or Middle East Respiratory Syndrome virus. Inovio is recruiting for its collaborative MERS vaccine trial with GeneOne Life Sciences in partnership with the Walter Reed Army Institute of Research where the trial is being conducted. The primary and secondary goal of this first-in-man phase I trial are to obtain safety and immunogenicity data. This trial represents the first and still only MERS vaccine to be tested in humans for this disease that has no approved vaccines or treatment. They expect to report interim data later this year.


NEWLINK GENETICS: Has received more than $74 Million in non-dilutive grants for a global HIV vaccine, Ebola Vaccine and others vaccines & treatments where their products have an advantage- including Mers & Zika.

ZIKA: Thomas P. Monath M.D., Chief Science Officer and Chief Operating Officer for the Infectious Disease Division of NewLink Genetics and an internationally-recognized expert on flaviviruses presented June 1, 2016 at "What Does the Biology of Flaviviruses Tell Us About Zika: The Importance of Fundamental Virus Biology," scientific conference focused on the Zika virus hosted by the American Society for Microbiology (ASM) in collaboration with the American Society for Virology (ASV). Title of his presentation was "Cognate Pathogenesis of Neurotropic Flaviviruses Relevance to Vaccine Development."

Dr Monath has led development of new vaccines against flaviviruses including dengue, West Nile, Japanese encephalitis and yellow fever. His presentation at the ASM conference focused on the common themes in pathogenesis and vaccine development between Zika virus and other members of the flavivirus group.

In Feb, 2016 they announced they expect the first Human Zika trial before the end of this year.


EBOLA: 4.25.16 Awarded $21.6 Million Contract Option by BARDA (Biomedical Advanced Research and Development Authority of US Dept. Health & Human Services) for Ebola Vaccine Development. These funds will be used to conduct clinical bridging studies to further assess the vaccine's safety, immunogenicity and efficacy in populations different from the original testing region.

It received the Best Prophylactic Vaccine award at the 15th Annual World Vaccine Congress in 2015.

Their Ebola vaccine candidate was found to have 100% efficacy in an analysis of interim data from a Phase 3 ring vaccination trial in Guinea.

"BARDA is providing pivotal support and commitment to accelerated development of this Ebola vaccine candidate," said the CEO.

Newlinks has partnered with Merck since Nov. 2014 on the Ebola vaccine with milestone payments of $50 million as part of their agreement.


CHIKUNGUNYA: Newlink published in the first quarter 2016 their novel dMAb antibody and DNA vaccine targeting the Chikungunya virus provided 100% protection against the lethal virus challenge in pre-clinical settings.

MERS: Clinical trial has begun.

DENGUE VIRUS, preclinical trials provided 100% protection against the lethal dengue virus challenge in laboratory animals and will now be moving into human clinical trials.


A couple other companies well advanced in their area of expertise for Zika:

CERUS: In Feb. 2016 received approval of their system which is effective in eliminating Zika from the blood supply. Cerus is a biomedical products company focused in the field of blood transfusion safety.
The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as Chikungunya, malaria and dengue and now Zika.


Up to now, the only Zika test available requires blood samples being sent off to the FDA laboratory for testing with the attendant lag time for a response. The FDA is so inundated with Zika tests, they are subbing some of the work out to a few other qualified labs. 31 Companies were cited by WHO in March as working on diagnostics for this very reason. The leader..

CHEMBIO DIAGNOSTIC SYSTEMS in Feb., 2016 WHO announced Chembio is working on a portable, rapid-results Zika test.  It aimed to show from a drop of blood from a fingertip whether someone is infected.

In Feb., 2016 they received a $550,000 grant from the Paul Allen Family Foundation to immediately initiate development of simple, cost-effective POC (Point of Care) diagnostic tests to identify Zika virus and related febrile illnesses.

They are currently seeking approval from the Brazilian regulatory agency for their point of care test in collaboration with Bio-Manguinhos. They have already conducted tests of DPP® Zika IgM/IgG Assay with nearly a thousand clinical samples from Brazil, Colombia, Dominican Republic,
El Salvador, Malaysia, Mexico and the United States. You can be sure applications will be forthcoming to regulatory agencies in many other countries.

They also have received grants to develop a DPP® Fever Panel Assay, capable of simultaneously detecting Malaria, Dengue, Chikungunya, Ebola, Lassa, and Marburg with a single drop of blood from the fingertip. They are well-positioned to act quickly, given their ongoing collaborations with Centers for Disease Control and Prevention (CDC), Brazil's Ministry of Health, and the global scientific community.


So, you see, just in noting these few companies, the newly formed œOpen Zika Project is well behind the curve of the 67+ companies noted by WHO. The scientific community and other bio-techs in most aspects of Zika research are well ahead of them. Products are already appearing on the market with more to follow. Zika and these other related diseases are not œneglected/orphaned nor in need of BOINC involvement to find and develop prospective diagnostics, vaccines or therapeutics. With several Ebola vaccines in Phase 1 to Phase 3 human trials with excellent results to date and Zika approaching or going into human clinical trials this year by several bio-techs and govt. researchers, I believe our computing time would be better served working on Mapping Cancer Markers, œUncovering Genome Mysteries, working on other diseases such as the Marburg Virus and Lassa Virus the Outsmarting Ebola project is moving on to, the Help Stop TB project and the Fight AIDS @ Home Phase 2 project. These are all truly open source medical studies and are helping the world research community make progress in understanding and fighting these diseases and their mutations.